Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

INTRODUCTION: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuznik, Andreas, Bégo-Le-Bagousse, Gaëlle, Eckert, Laurent, Gadkari, Abhijit, Simpson, Eric, Graham, Christopher N., Miles, LaStella, Mastey, Vera, Mahajan, Puneet, Sullivan, Sean D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698200/
https://www.ncbi.nlm.nih.gov/pubmed/28933010
http://dx.doi.org/10.1007/s13555-017-0201-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698200/
https://www.ncbi.nlm.nih.gov/pubmed/28933010
http://dx.doi.org/10.1007/s13555-017-0201-6

Ejemplares similares